Company news: Bayer, EMA

Share this article:
Bayer landed the FDA's first approval of a new IUD in more than a decade. The new contraceptive, known as Skyla, will be available February 11. The IUD can stay in place for up to three years and is for women regardless of whether or not they have been pregnant. Bayer said it is 99% effective in preventing pregnancies. The company also makes the IUD Mirena, which was approved in 2001.

European Medicines Agency is looking to add an additional $24 million dollars to its budget and will do so by raising fees, reported InPharma. The additional revenue is meant to keep pace with the anticipated 4% spending increase it has budgeted for 2013. The EMA is also raising revenue by reducing its financial Orphan Drug support and will reduce the fee reduction for non-pediatric drugs from 75% to 40%.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.